Breaking news and analysis from the world of science policy

  • Killing badgers not enough to defeat costly tuberculosis in cattle, U.K. report finds

    a badger at night

    European badgers can spread tuberculosis to cattle, but killing the animals to prevent outbreaks has led to controversy.

    mike lane/Alamy Stock Photo

    One of the most contentious wildlife management debates in the United Kingdom is whether badgers must be killed in order the slow the spread of tuberculosis (TB) in cattle, a disease that costs farmers and taxpayers about £120 million a year. Farmers insist the culling is necessary, because badgers can spread the disease to cattle. Wildlife advocates counter that the practice is inhumane and can make the problem worse.

    A new review of the issue, released today, reaffirms that badgers are partly responsible, but urges farmers to do more to protect their herds and prevent inadvertent spread of the disease. “It is wrong to put all the blame on wildlife,” said population biologist Charles Godfray of the University of Oxford in the United Kingdom, an author of the review. “This is a disease that needs action on all fronts.”

    Bovine TB is the “most pressing animal health problem in the U.K.,” according to the review. The strain that infects cattle is killed by pasteurizing milk, but sick animals produce less milk and lower quality meat. Infected animals are typically killed. The disease been particularly difficult to control in the United Kingdom and is getting worse, in part because badgers are also susceptible. The bacteria can spread between cattle and badgers that live near farms. In 2014, the U.K. government launched a 25-year strategy to eradicate the disease with a combination of testing, controls on cattle movements, and a controversial plan to kill badgers. The justification for the culling comes from a large randomized trial that took place between 1998 and 2005. It found that culling can reduce the number of TB cases in cattle, but only if at least 70% of the badgers around a farm are killed. Killing fewer can disrupt the social structure of badger communities, causing some to travel farther away and potentially spread the disease.

  • Drug for rare disease disappoints in key trial

    Hugh and Chris Hempel with their daughters Addi and Cassi

    The Hempel family, pictured when twins Addi (left) and Cassi (second from right), who both have Niemann-Pick type C, were about 11 years old. Chris Hempel (right) says the twins, now 14, have been helped by spinal injections of cyclodextrin.


    A treatment for Niemann-Pick type C (NPC), an extremely rare and ultimately fatal neurodegenerative disease, performed no differently than placebo in a pivotal trial in 56 children and youths, its corporate sponsor announced on Tuesday. Perplexingly, though, the disease did not progress in either the treatment or placebo groups during the 1-year study, the company said. Normally, the condition, a result of impaired cholesterol metabolism, inexorably worsens, causing loss of balance, difficulty swallowing, seizures, and cognitive disabilities.

    The drug, VTS-270, a doughnut-shaped sugar molecule called a cyclodextrin, “did not show a statistically significant separation from placebo,” Steven Romano, Mallinckrodt Pharmaceuticals’s executive vice present and chief scientific officer told investors on a conference call on Tuesday. “But importantly, neither did [patients in the active or placebo arms of the trial] show disease progression as would have been anticipated in the neurodegenerative condition over 52 weeks of observation.” The drug was given by spinal injection into the cerebrospinal fluid, which circulates to the brain.

    The news—and the way Mallinckrodt, which has its U.S. headquarters in St. Louis, Missouri, delivered it—came as a shock to families in the NPC community, who learned of it when investors began to tweet about it. (The company did email a letter to NPC disease groups on Tuesday. Mallinckrodt, whose stock is publicly traded, added in a statement emailed to Science that securities laws prevented the company from notifying patients sooner.)

  • Open-access plan draws online protest

    people are reading or working on the computers inside the modern central Public Library of Amsterdam

    Open-access journals’ article processing charges are often paid by research organizations’ libraries.


    Hundreds of scientists are pushing back against Plan S, a plan to crack down on scholarly journals’ paywalls, launched 2 months ago by 11 national research funders in Europe. In an open letter published on 5 November, about 800 signatories say they support open access (OA)—making papers available free to all readers online—but condemn Plan S as “too risky for science.”

    The letter slams the plan’s decision to stop paying for researchers to publish in so-called “hybrid” journals of scientific societies such as the American Chemical Society. Hybrid publications earn revenue from both reader subscription fees and article processing charges (APCs) paid by authors who want to make their papers immediately accessible. “Effectively Plan S would block access to exactly those journals that work with a valuable and rigorous peer-review system of high quality,” the letter says.

    Robert-Jan Smits, OA envoy for the European Commission in Brussels and one of the architects of Plan S, says he has “enormous respect” for the work of learned societies, but no tolerance for some journals’ “sometimes outrageous” subscription fees. Hybrid journals were meant as a step to help subscription journals move toward full OA, he says, but they have endured as profitmaking ventures that rely on public funding, without a clear exit in sight.

  • Hospital’s suspension of evidence-based medicine expert sparks new controversy

    Rigshospitalet  in Copenhagen, Denmark, August 4, 2017

    The researcher at the center of a controversy roiling Cochrane, an international network of doctors and researchers, headquartered in London, that promotes evidence-based medicine, has been suspended as head of the Nordic Cochrane Centre in Copenhagen. Peter Gøtzsche, who was a founding member of Cochrane in 1993, has attracted attention for his outspoken critiques of pharmaceutical companies—and sometimes of Cochrane itself. In September, Cochrane’s governing board voted to remove him for “a consistent pattern of disruptive and inappropriate behaviours.” That decision led four other board members to resign in protest. Two weeks later, Gøtzsche said he would withdraw the Nordic Cochrane Centre from the international organization.

    That was unacceptable to the board, however. In an interview with Science last month, Cochrane co-chair Marguerite Koster, a senior manager at Kaiser Permanente, said Cochrane CEO Mark Wilson would try to convince the Rigshospitalet in Copenhagen and the Danish government, which funds the Nordic Cochrane Center, to keep the center within the collaboration. Because he’s been ousted as a member, “Peter Gøtzsche no longer is the director of the Nordic Cochrane Center,” she argued. The board also took control of the website for the center and removed Gøtzsche’s statements about the case from it; he has since posted updates about the fight on his own website.

    It’s unclear whether Cochrane’s lobbying has had any effect, but yesterday, the Rigshospitalet, which hosts the Nordic Cochrane Centre, announced it had suspended Gøtzsche. “We're striving to ensure that the Nordic Cochrane Centre continues as part of the international Cochrane Collaboration,” Deputy Chief Executive Per Jørgensen said in a statement. A spokesperson told Science the hospital would not give any further reasons for the suspension. Assistant Director Karsten Juhl Jørgensen has been appointed as acting head of the center, and the hospital has asked the University of Copenhagen to take over supervision of its graduate students.

  • From Science Careers: NSF moves to pilot LGBT questions on national workforce surveys

    a hand painted with a rainbow flag

    Every year, after clicking “submit” on the final copies of their Ph.D. dissertations, thousands of scientists answer all sorts of questions—for example, about their age, sex, race, ethnicity, and career plans—as part of the U.S. National Science Foundation’s (NSF’s) Survey of Earned Doctorates (SED). The questionnaire has served as an annual census of U.S. doctoral degree-grantees since 1957 and provides useful demographic information, which can be used to track the success of diversity efforts. In the years ahead, the survey may start covering even more ground: During a meeting last week at NSF’s headquarters in Alexandria, Virginia, the agency said it plans to test the feasibility of adding questions about sexual orientation and gender identity.

    NSF’s move was catalyzed by a letter arguing that comprehensive, nationwide data on LGBT (lesbian, gay, bisexual, and transgender) scientists and engineers are needed because the group experiences disadvantages and disparities that are akin to other underrepresented groups, such as racial and ethnic minorities and women. Only a handful of studies have examined LGBT representation in STEM (science, technology, engineering, and math) graduate programs and the scientific workforce, so there’s a clear need for more information, says Jonathan Freeman, an associate professor of psychology at New York University in New York City and the lead author of the letter. The letter writers used LGBT—rather than, say, LGBTQ—because it’s the most generally recognized term, and they didn’t want to confuse audiences who may not be as familiar with others. “In wanting to have a conversation with folks about these issues, oftentimes it’s a way to meet them where they’re at in terms of language,” says letter co-author Laura Durso, the vice president of the LGBT Research and Communications Project at the Center for American Progress in Washington, D.C.

    The letter writers asked NSF to include questions about sexual orientation and gender identity on the SED, as well as two biennial surveys administered by the agency: the Survey of Doctoral Recipients and the National Survey of College Graduates (NSCG), both of which are designed to examine the career trajectories of STEM degree holders living in the United States. The letter was cosigned by 251 scientists, engineers, and legal and public policy scholars, as well as 17 scientific organizations (including AAAS, which publishes Science Careers).

    If LGBT data were available from these surveys, “you’d have tons of people chewing on these data” to figure out if and where underrepresentation exists and to suggest interventions, Freeman says. Data collected by NSF could help us understand a whole host of questions about STEM’s LGBT community—“whether they’re here, whether they’re being retained, what their work trajectory is, whether they get paid as much”—notes Lauren Esposito, an assistant curator at the California Academy of Sciences in San Francisco and cofounder of the 500 Queer Scientists visibility initiative.

    NSF is still in the early planning stages, so details are sparse regarding how it will move forward. But a spokesperson told Science Careers via email that changes to demographic data collection require a “lengthy, deliberate process involving extensive experimentation” in order to ensure that the agency generates “accurate, reliable data sets.” NSF plans to start with the biennial NSCG. The earliest that LGBT questions would be added is 2021 because the window for testing questions to add to the 2019 survey has passed.

    Durso, who has worked to add sexual orientation and gender identity questions to federal surveys across the U.S. government, understands why implementing changes to the survey will take time. “There’s actually quite a bit of testing that has to happen,” says Durso, who holds a Ph.D. in clinical psychology and has studied the LGBT community. “These are federal government surveys; you want to do a deliberate and well thought out process.” For instance, it’s important to get the wording right to ensure that people fully understand the question that they’re being asked. Before making any changes to an ongoing survey, statisticians also want to confirm that adding certain questions won’t cause some people to refuse to answer the survey entirely—for instance, because they are offended by the questions.

    Esposito is also concerned that collecting this type of information could be risky for the survey respondents themselves. Esposito—who hadn’t read the letter that was sent to NSF until Science Careers emailed her a copy—agrees that there’s a need for the data. “We should be informed and have tools at hand by which we can make policy and bring about change,” she says. But she worries about these kinds of data being in the hands of the federal government. “Sexual orientation and gender are not protected classes federally and in many states in this country,” she notes. When “you can be fired for that information, it seems risky and it seems like a risk that many people would have to think twice before taking,” she says.

    Told about Esposito’s concerns, letter co-author Adam Romero—the director of legal scholarship and federal policy at the University of California, Los Angeles School of Law—acknowledged her concerns but expressed confidence that they were not a reason to scrap the survey questions. “In my experience, the federal government does a very good job to keep the personal demographic and other responses of survey takers highly confidential and protected,” he says. In addition, existing federal surveys that ask these kinds of questions usually give an option to decline to answer or to say that you don’t know. “For any particular person who may be uncomfortable, there’s no mandate to disclose their sexual orientation or gender identity.”

    Policy decisions in higher education often hinge on information gleaned from federal surveys, notes Bryce Hughes, an assistant professor of education at Montana State University in Bozeman. So if NSF doesn’t collect data on sexual orientation and gender identity, then “we’ll miss opportunities” to make policy decisions that benefit LGBT communities, he says. “I’m just excited to see this moving forward.” Hughes wasn’t involved with the push to nudge NSF to add LGBT questions, but he understands the value of these kinds of data: Earlier this year, he published a study showing that sexual minorities are more likely to leave STEM undergraduate programs than their heterosexual peers.

    Freeman—the author who spearheaded the letter—wants to get data into the hands of Hughes and other social scientists because he’s concerned that LGBT issues have been sidelined in STEM diversity discussions. “There is a tendency to see LGBT information … [as an] overly personal demographic detail … that should have no place in science and engineering,” Freeman says. But he says that people shouldn’t view it that way. “This is about a social identity that is like any other, like gender or race or ethnicity.” That’s why it’s important to have LGBT role models and adequate representation across STEM fields, he says.

    “These are scientists and engineers, and so numbers speak and data speak, and I think having actual data on this would really change things,” Freeman says. “I think it would trigger a snowballing event of getting more people to study this issue and getting universities and federal funding agencies” to think about LGBT diversity initiatives, he says.

  • Climate and energy measures fall flat in Colorado and Washington

    A drilling pad in front of a housing development

    Oil and gas development in Colorado.

    RJ Sangosti/The Denver Post/Getty Images

    A number of states had climate- and energy-related measures on the ballot yesterday. Here is how two of the most prominent measures fared:

    In Washington, carbon tax fails

    Voters decisively rejected, by 56% to 43%, a push to become the first U.S. state to tax greenhouse gas emissions for the second time in 2 years. The defeat of Initiative 1631 came after a nearly $32 million opposition campaign funded chiefly by some of the world’s largest oil companies. BP America, the largest donor, pumped in more than $12 million.

  • Some takeaways for science from yesterday’s U.S. elections

    I Voted sticker
    Bored-now/Flickr (CC BY-NC-ND 2.0)

    For scientists, the new Democratic majority in the U.S. House of Representatives isn’t the only important result from last night’s midterm election. Although some races are still too close to call, and others are awaiting the counting of early votes and absentee ballots, here are some other highlights:

    Four House incumbents active on science issues have been defeated, and a fifth is trailing.

  • In win for open access, two major funders won't cover publishing in hybrid journals

    wellcome trust

    Headquarters of the Wellcome Trust in London

    Edward/Public Domain

    Plan S, the open-access (OA) initiative launched by the European Commission and Science Europe in September, has gained two major new members. The Wellcome Trust and the Bill & Melinda Gates Foundation—two of the world’s largest private foundations that support research—announced today they are joining a consortium of 11 European funding agencies in requiring their funded research to be immediately free for all to read on publication.

    The two new partners add a lot of funding muscle to the effort to require scientists to publish their papers in journals that make their content free to the public, instead of charging subscriptions. The existing Plan S coalition partners, represented by Science Europe, collectively spend about $8.7 billion on research. Wellcome, based in London, funds about $1.3 billion of biomedical research per year, whereas the Seattle, Washington–based Gates Foundation spends more than $1.2 billion on global health R&D.

    The largest part of the policy change is that as of January 2020, Wellcome and Gates will no longer cover the cost of their grantees publishing in so-called hybrid OA journals, which have both subscription and free content. Most scientific journals now follow that hybrid business model, which allows authors to pay a fee if they want to make their articles OA. For the past decade, Wellcome has allowed its grantees to pay these fees, in part because it viewed them as a way to help publishers finance a switch in their business models to full OA. “We no longer believe it’s a transition,” says Robert Kiley, head of open research at Wellcome. “We’re looking to bring about a change where all research is open access.”

  • NSF reviewing program that allows graduate fellows to study abroad

    international departure board showing canceled flights

    UPDATE: The National Science Foundation (NSF) said today that it is “currently reviewing possible future directions” for the Graduate Research Opportunities Worldwide (GROW). Amanda Greenwell, head of NSF’s Office Of Legislative and Public Affairs, said the agency “expects to make an announcement within the coming weeks” but that it “will not be publicly discussing the topic during the decision making process.” Greenwell also said the number of GROW recipients has declined over the past 3 years, from 158 in 2016 to 88 this year.

    Here is our previous story from 1 November:

    The U.S. National Science Foundation (NSF) has halted a program that each year allows hundreds of the nation’s best graduate students to work with experts in another country. And the agency isn’t saying why—or whether the program will resume.

    Begun in 2013, Graduate Research Opportunities Worldwide (GROW) is a perk of NSF’s flagship Graduate Research Fellowship (GRF) program. Students already receiving the $34,000-a-year fellowship can apply for an additional $5000 GROW allowance to cover travel and living expenses incurred while working in one of 17 countries. NSF has budgeted for up to 400 GROW awards a year (2000 GRFs are chosen annually) for foreign collaborations lasting from 3 to 12 months.

  • Record number of monkeys being used in U.S. research

    a rhesus macaque monkey grooming another

    Rhesus macaques are among the most popular nonhuman primates used in biomedical research.

    AP Photo/Brennan Linsley

    The number of monkeys used in U.S. biomedical research reached an all-time high last year, according to data released in late September by the U.S. Department of Agriculture (USDA).

    The uptick (see graph below)—to nearly 76,000 nonhuman primates in 2017—appears to reflect growing demand from scientists who believe nonhuman primates are more useful than other animals, such as mice or dogs, for testing drugs and studying diseases that also strike humans.

    “I think the numbers are trending up because these animals give us better data. … We need them more than ever,” says Jay Rappaport, director of the Tulane National Primate Research Center in Covington, Louisiana, which houses about 5000 monkeys. The increase also comes amidst a surge in funding from the National Institutes of Health (NIH), which supports much of the nonhuman primate research in the United States.

  1. « 1
  2. ‹ previous
  3. 1
  4. 2
  5. 3
  6. 4
  7. 5
  8. 6
  9. 7
  10. next ›
  11. 682 »